X0508 4 2025-05-12 true 0001743881 BridgeBio Pharma, Inc. BBIO 0001780408 KKR Genetic Disorder L.P. 30 HUDSON YARDS NEW YORK NY 10001 true 0001780428 KKR Genetic Disorder GP LLC 30 HUDSON YARDS NEW YORK NY 10001 true 0001472698 KKR Group Partnership L.P. 30 HUDSON YARDS NEW YORK NY 10001 true 0001743754 KKR Group Holdings Corp. 30 HUDSON YARDS NEW YORK NY 10001 true 0001932162 KKR Group Co. Inc. 30 HUDSON YARDS NEW YORK NY 10001 true 0001404912 KKR & Co. Inc. 30 HUDSON YARDS NEW YORK NY 10001 true 0001472694 KKR Management LLP 30 HUDSON YARDS NEW YORK NY 10001 true 0001081714 KRAVIS HENRY R C/O KOHLBERG KRAVIS ROBERTS & CO. L.P. 30 HUDSON YARDS NEW YORK NY 10001 true 0001081715 ROBERTS GEORGE R C/O KOHLBERG KRAVIS ROBERTS & CO. L.P. 2800 SAND HILL ROAD, SUITE 200 MENLO PARK CA 94025 true false Common Stock 2025-05-12 4 S 0 6000000 34.2 D 13260971 I See footnotes Reflects the sale of 6,000,000 shares of common stock of BridgeBio Pharma, Inc. (the "Issuer"), par value $0.001 per share (the "Common Stock"), by KKR Genetic Disorder L.P. in a block sale at a price per share of $34.20 pursuant to Rule 144 of the Securities Act of 1933, as amended. The shares of Common Stock are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC is the general partner of KKR Genetic Disorder L.P. KKR Group Partnership L.P. is the sole member of KKR Genetic Disorder GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP but disclaim beneficial ownership of the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein. See Exhibit 99.1 2025-05-14